Defects of taste and smell in patients with hypothyroidism.
Taste and smell functions were measured in 18 unselected patients with untreated primary hypothyroidism, and in 15 of the 18 patients after treatment with thyroid hormones. Before treatment, 9 of the 18 patients (50 per cent) were aware of some alteration in their sense of taste, and 7 of the 18 patients (39 per cent) were aware of some alteration in their sense of smell. Distoritions of tase (dysgeusia) and smell (dysosmia) were frequent complaints among the untreated patients; dysgeusia was observed by 7 patients (39 per cent) and dysosmia by 3 patients (17 per cent). Median detection and recognition thresholds for four taste stimuli salt (sodium chloride), sweet (sucrose), sour (hydrochloric acid) and bitter (urea), and for two smell stimuli (pyridine and nitrobenzene), were determined in each patient before and after treatment with thyroid hormones. Before treatment, decreased taste acuity (hypogeusia) for at least one stimulus was observed in 14 of the patients (83 per cent); the most common abnormalities were in the detection and recognition of bitter stimuli. Median detection thresholds for both smell stimuli were also markedly elevated (hyposmia) before therapy. Treatment with throid hormones largely reversed both the taste and smell defects. In one patient, taste and smell abnormalities were completely corrected after 16 days of treatment with thyroxine. This study indicates that taste and smell defects are common clinical abnormalities in primary hypothyroidism, and suggests that these defects may contribute to the anorexia and lack of interest in eating which are frequently observed.
D000328:Adult; D000368:Aged; D004408:Dysgeusia / Q000150:complications*; D005260:Female; D006801:Humans; D006851:Hydrochloric Acid; D007037:Hypothyroidism / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes; D011725:Pyridines; D012903:Smell; D012965:Sodium Chloride; D013395:Sucrose; D013649:Taste; D013651:Taste Disorders / Q000150:complications*; D013974:Thyroxine / Q000627:therapeutic use; D014284:Triiodothyronine / Q000627:therapeutic use; D014508:Urea
D009578:Nitrobenzenes; D011725:Pyridines; D014284:Triiodothyronine; D012965:Sodium Chloride; D013395:Sucrose; D014508:Urea; D013974:Thyroxine; D006851:Hydrochloric Acid